April 14, 2026 | Read online

Don’t Miss This: Add (MDCX) to Your Radar Before Tomorrow Morning

Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Medicus Pharma Ltd.

See Why (MDCX) Will Be Topping Tomorrow Morning’s Watchlist —Wednesday, April 15, 2026

April 14, 2026

Dear Reader,

Medicus Pharma Ltd. (NASDAQ: MDCX) just caught my attention.

The company recently submitted an optimized Phase 2 protocol to the U.S. FDA for Teverelix® in acute urinary retention, according to the April 6 press release — targeting a $2B addressable market where no approved pharmacologic therapies exist.

That's a wide-open lane. When a sub-$20M market cap biotech enters a space with zero competition, something could be brewing.

Keep reading to see why we're highlighting (MDCX) right now.

According to Grand View Research, the global Basal Cell Carcinoma treatment market is projected to hit $5.93B by 2030.

At the center of this expanding space is a company quietly advancing two potentially disruptive therapeutics.

Medicus Pharma Ltd. (NASDAQ: MDCX) will be topping our watchlist tomorrow morning— Wednesday, April 15, 2026.

According to Yahoo Finance, (MDCX) has 32.82M shares in its public float—with a float that small, the potential exists for big moves if demand begins to shift.

Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range.

What Does Medicus Pharma Do?

Medicus Pharma is a precision-guided biotech accelerating novel therapeutics across oncology and urology. Its lead asset, SkinJect™, is a patented dissolvable microneedle array delivering doxorubicin locally for non-invasive BCC treatment via a 505(b)(2) pathway.

Its second asset, Teverelix®, is a next-generation GnRH antagonist for advanced prostate cancer and acute urinary retention recurrence.

Here's where it gets interesting — both assets are hitting key milestones at the same time.

Pipeline Milestones Worth Watching

Teverelix® Phase 2 Submitted to FDA: According to the April 6 release, the study enrolls ~126 patients across the U.S. and Europe with an interim analysis at ~50% enrollment.
SkinJect™ Phase 2 — ~80% Overall Response Rate: The April 1 release confirmed 73% clinical clearance and 40% histological clearance in the 200-µg cohort. KOL Dr. Babar Rao validated the dataset independently.
EOP2 FDA Meeting on Deck: Targeting first half of 2026 for SkinJect™ — a critical registrational step.
AI-Driven Analytics Partnership: Medicus partnered with Reliant AI Inc. for agentic AI-enabled clinical data analytics, according to the March 26 update.
National Media Campaign: A 12-part New to The Street series launched April 2026 on Bloomberg TV and FOX Business.

And when you zoom out to the broader market, the timing of these potential catalysts looks even more compelling.

Market Alignment

Here's the addressable pipeline according to the March 26 update:

SkinJect™: ~$2B for non-melanoma skin cancers including Gorlin Syndrome
Teverelix® (AURr): ~$6B with zero approved pharmacologic competition
Combined Pipeline: ~$8B total addressable market

So let's bring it all together — here's why (MDCX) caught our attention for tomorrow.

4 Reasons (MDCX) Will Be Topping Our Watchlist

1. Limited Float: Just 32.82M shares per Yahoo Finance and a ~$16.12M market cap per Yahoo Finance — momentum can accelerate fast with this structure.

2. Dual Potential catalysts Stacking: ~80% ORR for SkinJect™, a freshly submitted Teverelix® protocol, and an EOP2 FDA meeting — all in one quarter. The Teverelix® study was refined under Dr. Steven A. Kaplan, a globally recognized BPH and urology authority from Mount Sinai.

3. Uncontested Market + National Visibility: Teverelix® targets AURr where zero therapies exist, and the New to The Street campaign on Bloomberg TV and FOX Business could amplify awareness at a critical moment.

4. Analyst Target: Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range.

Take a Look at (MDCX) Before Tomorrow Morning…

Tight 32.82M share float, ~80% Phase 2 response rate, a freshly submitted FDA protocol targeting $2B uncontested, and a combined ~$8B addressable pipeline — could (MDCX) be setting up for a reversal from these levels?

We will have all eyes on (MDCX) tomorrow, Wednesday, April 15, 2026.

Sincerely,

Ryan Stryker
Senior Editor
Alpha Wire Daily

_{AlphaWireDaily.com}_{(“AlphaWireDaily” or “AWD” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and AWD is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile AWD brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, GG Media Holdings LLC has been paid forty four thousand five hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (MDCX:US).}

_{Please see important disclosure information here:}_{https://alphawiredaily.com/disclosure/mdcx-7E33I/#details}